Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

More documents

Recommendations

Info

oms-catalogue 15/07/03 11:36 Page 30 WHO COLLABORATING CENTRE FOR INTERNATIONAL DRUG MONITORING The WHO Collaborating Centre for International Drug Monitoring 30 This WHO Collaborating Centre is situated in Uppsala Sweden and known throughout the world as the Uppsala Monitoring Centre. The UMC supports WHO's leadership in the field of world health by providing excellence • in the science and concepts of all aspects of pharmacovigilance • to prevent harm to humans from the effects of medicines • to gather and share objective intelligence and opinion in the field of drug safety through open and transparent means of communication • to support the promotion of the rational use of drugs, and the achievement of improved patient therapy and public health • in global education and communications in benefit, harm, effectiveness and risk in medical therapy It achieves this by • developing leading-edge systems and science for the identification and communication of safety hazards in drugs and other substances used in medicine • carrying out research pushing forward the ethical, intellectual and scientific boundaries of theory and practice in pharmacovigilance • pursuing active collaboration and communication with all stakeholders • pursuing the goal of a single, global database for drug safety data And in particular it aims to • ensure that effective, timely international collective effort will never miss a signal of a potential hazard • ensure that all stakeholders evaluate and learn from decisions and actions through positive impact-assessment, follow-up and debate • encourage the growth of pharmacovigilance activities around the world, in particular the establishment of new National Centres • promote existing National Centres and other stake holders in the field • to contribute actively to the global vision of the WHO Programme • to use and share available information openly and transparently • to sponsor and support others in their pharmacovigilance activities • to exploit fully the resources of the UMC • stimulate the development of coherent, harmonised systems worldwide for pharmacovigilance, through education, training, promoting and participating in international forums, the promotion of best practice and the publication of guidelines • maintain and develop useful products, services and tools in pursuit of the vision and goals of the WHO Programme and the UMC. Some key publications of the Uppsala Monitoring Centre are: • Viewpoint – Watching for Safer Medicines • Guidelines for setting up and running a Pharmacovigilance Centre • Pharmacovigilance in Focus • Uppsala Reports • Communicating Drug Safety <strong>Information</strong> - The Erice Declaration • Dialogue in Pharmacovigilance - more effective communication • Expecting the Worst –Anticipating, preventing and managing medicinal product crises • Guidelines for Herbal ATC classification • National Pharmacovigilance Systems • The WHO Adverse Reaction Terminology • The WHO Drug Dictionary For further information and publication orders, please contact: WHO Collaborating Centre for International Drug Monitoring Stora Torget 3 S-753 20 Uppsala, Sweden Tel: +46-18-656060 Fax: +46-18656080 Email: info@who-umc.org web site: www.who-umc.org
oms-catalogue 15/07/03 11:36 Page 31 MEDICINAL PLANTS Guidelines for the Appropriate Use of Herbal Medicines Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene Reports the findings and recommendations of a working group convened to prepare guidelines for the use of herbal medicines in Western Pacific countries. Addressed to national health authorities, the report responds to the widespread use of herbal medicines in this part of the world and the corresponding need for mechanisms to ensure that these products are safe and effective, yet remain broadly accessible. With this need in mind, the report sets out a comprehensive framework for developing national policies designed to control the safety, efficacy, and quality of herbal medicines, manufacturing practices, product registration, and labelling, marketing, and trade. Sets out detailed guidelines for conducting scientific research on the safety and efficacy of herbal medicines. The guidelines, which reflect the consensus reached by 17 experts in pharmacology, biochemistry, and traditional medicine, respond to the need to assure the safety of widely-used herbal medicines while also facilitating the search for new pharmaceutical products. Specific research criteria are covered together with general principles of investigation, including ethical concerns. Traditional herbal medicines encompass an extremely diverse group of preparations that originate from many different cultures. In recent years, such products have become widely available commercially in developed countries, where mixtures prepared from medicinal plants have been marketed or uses that were never contemplated in the traditional healing systems from which they emerged. This monograph evaluates the carcinogenic risks to humans posed by the use of some traditional herbal medicines, Fumonisin B1, and the industrial organic chemicals naphthalene and styrene, and provides an update of the data on the carcinogenicity of aflatoxins. An Annex to the volume describes fungal sources and formation of aflatoxins in foods and feeds, and discusses practical strategies for reduction of aflatoxin levels. 31 WHO Regional Office for the Western Pacific WHO Regional Publications, Western Pacific Series, No. 23 1998, vi + 79 pages [E] ISBN 92 9061 124 3 Swiss francs 7.50/US $6.70 In developing countries: Sw.fr. 5.20 Order no. 1510023 WHO Regional Office for the Western Pacific 1993, v + 86 pages [E] ISBN 92 9061 110 3 Swiss francs 7.50/US $6.70 In developing countries: Sw.fr. 5.20 Order no. 1520003 International Agency for Research on Cancer IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 82 2002, 500 pages [E] ISBN 92 832 1282 7 Swiss francs 55.-/US $49.50 In developing countries: Sw.fr. 38.50 Order no.1720082
Page 1 and 2: oms-catalogue 15/07/03 11:32 Page 1
Page 31: oms-catalogue 15/07/03 11:36 Page 2

Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

Create successful ePaper yourself

Delete template?

Save as template?